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ABSTRACT
Prostate cancer is an androgen receptor (AR)-driven disease and post-translational
modification of AR is critical for AR activation. We previously reported that Arrestdefective protein 1 (ARD1) is an oncoprotein in prostate cancer. It acetylates and
activates AR to promote prostate tumorigenesis. However, the ARD1-targeted residue
within AR and the mechanisms of the acetylation event in prostate tumorigenesis
remained unknown. In this study, we show that ARD1 acetylates AR at lysine 618
(K618) in vitro and in vivo. An AR construct with the charged lysine substitution by
arginine (AR-618R) reduces RNA Pol II binding, AR transcriptional activity, prostate
cancer cell growth, and xenograft tumor formation due to attenuation of AR nuclear
translocation, whereas, construct mimicking neutral polar substitution acetylation at
K618 by glutamine (AR-618Q) enhanced these effects beyond that of the wild-type AR.
Mechanistically, ARD1 forms a ternary complex with AR and HSP90 in vitro and in vivo.
Expression of ARD1 increases levels of AR acetylation and AR-HSP90 dissociation
in a dose dependent manner. Moreover, the AR acetylation defective K618R mutant
is unable to dissociate from HSP90 while the HSP90-dissociated AR is acetylated
following ligand exposure. This work identifies a new mechanism for ligand-induced
AR-HSP90 dissociation and AR activation. Targeting ARD1-mediated AR acetylation
may be a potent intervention for AR-dependent prostate cancer therapy.

INTRODUCTION

proteins within the cytoplasm, including HSP90,
preventing nuclear localization while maintaining
ligand access [7, 8]. Upon androgen binding, AR
undergoes a conformational change leading to ARHSP90 dissociation, rapid nuclear translocation, and AR
target gene transcription [9]. Unchecked, this process
eventually leads to prostate tumorigenesis. Disrupted AR
and HSP90 interaction via HSP90 inhibition has been
utilized as a therapeutic target in PCa clinical trials, but
with limited success thus far [10]. New approaches for
targeting the interaction of AR and HSP90, as well as the
androgen-driven AR nuclear translocation may provide
more efficacious therapeutic strategies while avoiding the
deleterious effects of ADT.

Androgen receptor (AR) plays a crucial role
in prostate cancer (PCa) [1, 2]. Activation of AR
via mutation, amplification, overexpression, or
posttranslational modification leads to PCa initiation
and progression [3–5]. Although androgen deprivation
therapy (ADT) is initially effective, the unconfined disease
inevitably overcomes the androgen blockade and recurs
as lethal castration-resistant PCa (CRPC) [6]. Alternative
strategies that inhibit AR activity without contributing to
disease progression are needed.
In prostate cells, prior to androgen binding,
AR is inactively bound to a foldosome of chaperone
www.impactjournals.com/oncotarget
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Posttranslational modification of AR, including
acetylation, plays a crucial role for AR activation [11].
To date, several acetyltransferases have been identified
to acetylate AR including p300 [12, 13]. P300 acetylates
AR at lysines KLKK633 and is critical for AR activation,
lncoRNA binding, and prostate tumor development
[13, 14]. Arrest defective-1 protein (ARD1, also known
as Naa10p) is another acetyltransferase [15, 16]. It
acetylates amino acids at the N-terminal of protein
(N-alpha-acetylation) or lysines within proteins (epsilonacetylation), both of which play important roles in several
types of cancer through acetylating different target proteins
[17–21]. Previously, we reported that the level of ARD1 is
consistently higher in PCa, and that ARD1 activates AR
through ARD1-mediated AR acetylation [22]. Moreover,
depletion of ARD1 diminishes LNCaP cell xenograft tumor
growth [22]. However, the specific target residue of ARD1mediated AR acetylation, has not yet been identified.
And the bio-pathological roles and mechanisms of AR
acetylation in AR activation and prostate tumorigenesis
have yet to be elucidated. These include AR and HSP90
interaction and AR nuclear translocation. Inhibition of an
AR activator that modulates both AR activity and ARHSP90 interaction could serve as a powerful, synergistic
strategy to suppress PCa progression.

and showed that the acetylation levels of the endogenous
AR in these cells are greatly reduced (Figure 1D). Next,
we transfected wild-type AR-K618 or mutant AR-618R
(in which the lysine was replaced by arginine) expression
construct in 293 cells and examined the acetylation level
of AR-K618 or AR-618R using an acetylation-specific
antibody. The result demonstrated that the absence of the
K618 site severely reduced the acetylation level of AR by
over 90 percent in vivo (Figure 1E). Since KLKK633 in AR
are the acetylation target for p300/Tip60, we transfected
mutant AR constructs in which either KLKK633 or both
KLKK633 and K618 were replaced by arginine to compare
the levels of in vivo acetylation. The results indicated
that absence of K618 severely limited acetylation, and
the absence of both K618 and K630/632/633 nearly
abolished AR acetylation (Figure 1F). Notably, loss of
the ARD1 target site had a much more negative impact
on AR acetylation level than the loss of the p300/Tip60
sites. Taken together, these data suggest that K618 is
the primary ARD1-specific acetylation target within AR
in vivo and in vitro.

ARD1-mediated acetylation enhances AR
activity
Next, we investigated the impact of ARD1-mediated
acetylation on the activity of AR. We created an AR-618R
mutant construct to abolish ARD1-mediated acetylation
and an AR-618Q mutant construct to mimic constitutive
acetylation. Using AR-negative DU 145 PCa cells, we
analyzed the impact of WT-AR-K618, mutants AR-618R
and AR-618Q on PSA-luciferase reporter activity. We
showed that AR-618Q enhanced the promoter activity, but
AR-618R significantly diminished the activity (Figure 2A).
In agreement, chromatin immunoprecipitation (ChIP)
analysis showed that expression of AR-618Q enhanced
its interaction with the PSA or TMPRSS2 promoters as
compared to WT-AR-K618, while AR-618R significantly
reduced promoter binding (Figure 2B, 2C). DU 145 cells
stably expressing each of the three AR constructs were
created. RNA from each of the three stable cell pools was
harvested and subjected to qRT-PCR analysis. While AR618Q enhanced AR target gene transcription as compared
to WT-ARK618, the presence of AR-618R inhibited it
(Figure 2D). In addition, AR-618Q co-immunoprecipitated
more readily with RNA polymerase II as compared to WTAR-K618, while the interaction of AR-618R with RNA
polymerase II was greatly reduced (Figure 2E). These data
demonstrated that ARD1-specific acetylation at lysine 618
enhances transcriptional activity of AR.

RESULTS
ARD1 acetylates AR at K618 in vitro and in vivo
We previously reported that ARD1 acetylates
AR but the AR acetylation site(s) targeted by ARD1 is
different from that of p300 which targets lysine residues
(KLKK633) [22]. To determine which lysine residue is
acetylated by ARD1, we synthesized GST-tagged AR
fragments and subjected them to in vitro acetylation assays
in the presence of in vitro synthesized His-ARD1 and
acetyl CoA, respectively (Figure S1). We demonstrated
that the DNA binding domain (DBD) of AR is strongly
acetylated by ARD1 (Figure 1A). Since DBD comprises
three lysine-containing motifs (Figure S2A), we then
created three DBD mutant constructs in which all lysines
in two motifs were mutated leaving one motif intact,
as well as one DBD-total mutant construct in which all
lysines in all three motifs were mutated (Figure S2B).
The DBD mutants were subjected to in vitro acetylation
assays again, and motif II was identified as the ARD1
target (Figure 1B). Motif II of the DBD contains three
lysines at residues 605, 609, and 618. To determine which
lysine in motif II is acetylated by ARD1, we mutated all
but one lysine, respectively, within motif II and again
subjected each DBD mutant to in vitro acetylation assay
(Figure S2C). Lysine 618 (K618) was identified as the
primary target of ARD1 (Figure 1C). These data suggested
that K618 is the ARD1 acetylation target in AR in vitro.
To determine if K618 is the ARD1-acetylated site
in vivo, we first silenced ARD1 by using shRNA in LNCaP
www.impactjournals.com/oncotarget

ARD1-mediated AR acetylation enhances
prostate tumorigenesis
To understand the pathological impact of ARD1mediated AR acetylation, we measured its tumorigenic
potential using pools of DU 145 cells stably expressing
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Figure 1: AR is acetylated by ARD1 at K618 in vivo and in vitro. (A–C) Immunoblots and graphs of normalized relative densitometry

of individual GST-AR fragments (A), of individual DBD lysine-containing motif-mutants (B), and of individual DBD single-lysine-WT
mutants (C) following in vitro acetylation assay and Western blot analyses with anti-acetylated lysine antibody. (D) Silencing ARD1 by
shRNA inhibits AR acetylation in vivo. Cell lysates from LNCaP cells transfected with shARD1 or controls were immunoprecipitated with
AR antibody; the level of acetylated AR was measured by Western blotting using the anti-acetylated lysine antibody. (E) Overexpression
of ARD1 increased acetylation level of WT-AR but not AR-618R mutant in vivo. Cell lysates from 293 cells co-transfected ARD1 with
WT-AR or AR-618R mutant construct were immunoprecipitated with AR antibody; the level of acetylated AR was measured by anti-acetylated
lysine antibody. (F) Immunoblot of in vivo acetylation of AR-WT, AR-618R, AR-618R/p300mut, or AR-p300mut, respectively. Cell lysates
from 293T cells co-transfected with ARD1 and each individual AR construct were immunoprecipitated with AR antibody and acetylation
levels were measured with anti-acetylated lysine antibody. All experiments were repeated at least thrice and the data were presented as the
mean of the experiments (± SEM). Significance of statistical analysis was indicated as *(p < 0.05), **(p < 0.01), and ***(p < 0.001).
www.impactjournals.com/oncotarget
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WT-AR-K618, or mutant AR-618R, or AR-618Q,
respectively (Figure 3A). Cells expressing AR-618Q
proliferated more rapidly, but AR-618R demonstrated
significantly decreased proliferation as compared to
AR-WT (Figure 3B). Consistently, cells expressing
AR-618Q or WT-AR-K618 grew larger, more abundant
colonies while AR-618R showed decreased anchorageindependent growth (Figure 3C). Moreover, cells
expressing AR-618Q slightly enhanced xenograft tumor

formation in male nude mice as compared with WTAR-K618, while AR-618R severely inhibited xenograft
tumor growth (Figure 3D). At the endpoint of this study,
the volume of xenograft tumors expressing AR-618R was
only one quarter of those expressing either AR-WT or AR618Q, and the initial growth point of tumors expressing
AR-618R was delayed by four weeks. Together, these data
suggest that ARD1-mediated AR acetylation at K618 plays
a critical role in prostate tumor growth.

Figure 2: ARD1-dependent acetylation enhances AR transcriptional activity. (A) Luciferase reporter assays in DU 145 cells

co-transfected with PSA-Luc reporter with AR-WT, AR-618R, AR-618Q, or empty vector respectively. Results presented as mean of
three replicates ± SD. (B and C) Differential binding of AR-WT, -618R, or -618Q to PSA and TMPRSS2 promoters by ChIP assays using
anti-AR antibodies. Normalized relative densitometry was shown above. (D) Quantification of in vivo expression levels of mRNA for
TMPRSS2 (AR positively-regulated ) and UGT2B15 (AR negatively-regulated) in DU 145 cells stably expressing AR-WT, AR-618R, AR618Q, or empty vector by qRT-PCR. Values represent the mean of triplicate experiments ± SD. (E) Immunoblot of co-immunoprecipitated
RNA polymerase II by transiently-transfected AR-WT, AR-618R, or AR-618Q in DU 145 cells.
www.impactjournals.com/oncotarget
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Acetylated AR is rapidly shuttled into the
nucleus

may lead to AR nuclear entry. Consistently, when we
transfected AR-WT, -618R, or -618Q into Cos-7 cells,
respectively, and subjected each cell group to one hour of
androgen exposure, AR-WT and AR-618Q rapidly entered
the nucleus while AR-618R demonstrated significantly
reduced ligand-dependent nuclear translocation (Figure 4B).
Western blot analysis confirmed less AR-618R present
in the nuclear fraction and much more present in the
cytoplasmic fraction as compared to the level of AR-WT
or AR-618Q post ligand exposure (Figure 4C). These data
indicate that ARD1-mediated AR acetylation at K618
enhances ligand-induced AR nuclear translocation.

Increased AR activity and RNA Pol II recruitment
following AR acetylation at K618 suggest that AR
acetylation by ARD1 may facilitate AR nuclear
translocation (Figure 2). To test this hypothesis, we cotransfected WT-ARD1 and GFP-tagged AR into Cos-7
cells and observed that AR readily translocated into the
nucleus (Figure 4A). In contrast, co-transfection of ARD1acetyltransferase-dead and AR displayed limited AR nuclear
translocation, suggesting that ARD1-mediated acetylation

Figure 3: AR Acetylation at K618 enhances prostate cell oncogenecity and xenograft tumor growth. (A, B) The growth

curves of DU 145 cell pools stably-expressing AR-WT, -618R, -618Q, or empty vector analyzed by MTT assays over a 5-day time course.
The data were presented as the mean of triplicate experiments (± SEM). Stable expression levels of AR are shown by Western blot (left).
(C) Anchorage-independent colony formation of the same DU 145 stable cells were assayed by seeding 3,000 cells in soft agar and
incubated for 21 days. Colonies (> 100 µm) were counted in each plate and presented graphically (right). (D) Tumor volumes of the DU
145 cells stably expressing each AR species in male nude mice measured weekly. The graphed results represent mean tumor volume ± SEM
(n = 3 mice/group). All of these cells were grown in RPMI phenol red-free 1640 media with 10% charcoal stripped FBS and the addition of
R1881 to 1 nM.
www.impactjournals.com/oncotarget
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Figure 4: ARD1-mediated AR acetylation at K618 enhances nuclear localization. (A) AR nuclear localization was analyzed

in Cos-7 cells co-transfected with GFP-tagged AR and ARD1-WT, ARD1-dead, or vector in the presence or absence of R1881 by
immunofluorescence and confocal microscopy. Proteins indicated include AR (green) or nuclear Dapi (red) stain (left). The percentage of
cells with nuclear AR is represented graphically (right) as a mean of three individual fields analyzed ± SD. (B) Cos-7 cells were transfected
with either AR-WT, AR-618R, or AR-618Q. After 24 hours serum-starvation, cells were treated with ethanol or 1 nM R1881 for one hour.
Nuclear localization was analyzed by immunofluorescence confocal microscopy with anti-AR antibody (green) and Dapi staining (blue).
Levels of nuclear AR are represented graphically as the mean of three independent fields’ ± SD (right) (C) Immunoblot of nuclear and
cytoplasmic fractionation of AR-WT, AR-618R, or AR-618Q in Cos-7 cells described above in the presence or absence of R1881 with
normalized relative densitometry (left). Nuclear versus cytoplasmic levels of AR-WT, AR-618R, or AR-618Q in the presence of R1881 are
represented graphically as the mean of three individual replicates ± SD (right).
www.impactjournals.com/oncotarget
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Acetylation of AR at K618 promotes androgeninduced AR-HSP90 dissociation

between HSP90 and the AR-K618 or the acetylation
mimetic AR-618Q mutant were greatly reduced, however,
the level of the acetylation defective AR-618R mutant was
not (Figure 5E; left 3 lanes). From these data, we conclude
that ARD1-mediated AR acetylation at K618 is required
for ligand-induced AR-HSP90 dissociation, which is
probably necessary for AR nuclear translocation, AR
target gene expression, and prostate tumorigenesis.

To determine the mechanism through which
ARD1-mediated
AR-acetylation
promotes
AR
activation and nuclear translocation, we first performed
sequential
coimmunoprecipitation
analyses
of
ectopically expressed ARD1 and AR proteins in 293T
cells and showed that ARD1, AR, and HSP90 form a
complex in vitro (Figure 5A). Consistently, reciprocal
coimmunoprecipitation analysis of the three proteins in
LNCaP cells demonstrated that they also form a complex
in vivo (Figure 5B). Intriguingly, following exposure to
ligand, the affinities of the three proteins in the complex
were greatly reduced resulting in dissociation of AR and
HSP90 from ARD1 (Figure 5C). Since androgen not
only induces ARD1-mediated AR acetylation but also
AR-HSP90 dissociation [7, 22], we next investigated
whether ligand-induced AR acetylation by ARD1 regulates
AR-HSP90 dissociation. We ectopically expressed AR
and Flag-HSP90 proteins with an increased amount
of Myc-ARD1 protein in LNCaP cells. We found that
without ligand induction, increased expression of ARD1
does not change the amount of HSP90-bound AR that
is immunoprecipitated with HSP90 nor the levels of AR
acetylation detected by acetylation-specific antibody
(Figure 5D; left 3 lanes). However, following ligand
induction, increased expression of ARD1 significantly
increases the level of AR acetylation but reduces the level
of HSP90-bound AR (Figure 5D; right 3 lanes). These
data indicate that ligand-induced AR-HSP90 dissociation
correlates with increased AR acetylation in an ARD1 dose
dependent manner.
The requirement of ARD1-mediated AR
acetylation for ligand-induced AR-HSP90 dissociation
was further analyzed. Sequential immunoprecipitation
analysis was employed to study the acetylation levels
of HSP90-associated- and dissociated-AR following
ligand induction. As expected, the acetylation level of
HSP90-bound AR immunoprecipitated with HSP90
was dramatically reduced following ligand exposure
(Figure 5F; left 2 lanes). However, after a second
immunoprecipitation with an acetylation-specific antibody
in the residual cell supernatant depleted of HSP90-AR
complexes, the HSP90-unbound AR was found to be
highly acetylated (Figure 5F; right 2 lanes), suggesting
that only acetylated AR dissociates from HSP90 complex
following ligand induction.
Finally, we investigated if ARD1-mediated
acetylation at AR K618 is responsible for ligand-induced
AR-HSP90 dissociation. When HSP90 was co-transfected
with AR-K618, AR-618R, or AR-618Q, respectively, we
observed that without ligand induction, the interaction
levels between HSP90 with AR-K618, AR-618R or 618Q
mutants were very similar (Figure 5E; left 3 lanes). But,
following ligand induction, the levels of dissociation
www.impactjournals.com/oncotarget

DISCUSSION
Androgen-induced AR dissociation from a complex
with HSP90 is the first step in AR activation. However,
the molecular mechanisms involved in this event remain
incompletely understood. In the present study, we
uncovered a new acetylation site in AR and demonstrated
that ARD1-mediated AR acetylation at K618 is required
for ligand-induced AR-HSP90 dissociation, AR activation,
and prostate tumorigenesis, and suggested a novel ARD1AR-HSP90 axis for therapeutic intervention (Figure 6).
In addition, we provided evidence that AR-acetylation
at K618 increases AR nuclear translocation (Figure 4).
It has been reported that ligand-induced AR nuclear
translocation can be mediated by Importin-7 or Hsp27
[23, 24]. However, our experiments demonstrated that
the mutant AR-618R does not affect AR-Importin-7 or
AR-Hsp27 interaction in LNCaP cells following ligand
exposure, suggesting that the process of ARD1-mediated
nuclear translocation seems to be Importin-7 or Hsp27independent (Figure S3, S4). Further analysis will be
required to understand the mechanisms by which ligandinduced AR-K618 acetylation by ARD1 facilitates AR
nuclear translocation in prostate tumorigenesis.
It is also worth noting that independent of K618,
AR K605 seems to also be acetylated by ARD1 relative
to the DBD-Total mutant (Figure 1C), though at a
significantly lower level than K618. We examined the
capacity of constitutive acetylation at K605 to induce
PSA-luc reporter activity and found that there was no
statistical difference between AR-WT and AR-605Q
(data not shown). This result indicates that low levels of
acetylation at K605 may not play a meaningful role in
ARD1-mediated AR activation.
The current rationale for HSP90 inhibitors is based
on blocking HSP90 ATPase activity with a nucleotide
mimetic, driving client protein proteolysis. To this date,
this strategy has demonstrated a limited clinical success
in the treatment of PCa [10, 25]. This result is likely due
in part to HSP90 targeting and inhibition of other client
proteins such as c-Src and ErbB-2 [26, 27]. Our finding
that ARD1-mediated AR acetylation at K618 activates
AR and induces ligand-dependent AR-HSP90 dissociation
offers a mechanism by which AR activation can be
interrupted independent of HSP90 inactivation.
In conclusion, we have identified a novel posttranslational activating modification of AR that promotes
71423
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Figure 5: ARD1-mediated AR acetylation drives ligand-induced AR-HSP90 dissociation. (A) His-AR and Flag-ARD1

were co-transfected in 293T cells. In vitro interaction of AR, ARD1, and HSP90 were analyzed by sequential immunoprecipitation
and immunoblotting with antibodies as indicated. (B) In vivo interaction of endogenous ARD1, AR, and HSP90 in LNCaP cells by
immunoprecipitation and immunoblotting using antibodies as indicated. (C) Immunoblot of interaction between AR-WT and Myc-ARD1WT transfected in Cos-7 cells in the presence or absence of R1881, immunoprecipitated with anti-Myc antibody. (D) AR and Flag-HSP90
were co-transfected with increased amounts of Myc-ARD1 in Cos-7 cells. Ligand-induced and ARD1 dose dependent AR acetylation
were measured by immunoprecipitation with an anti-AR antibody and immunoblotted with an antibody specifically against acetylated
lysine, while AR-HSP90 dissociation was measured by immunoprecipitation with an anti-Flag antibody and HSP90 co-immunoprecipitated
AR was observed by Western blot. (E) AR and Flag-HSP90 co-transfected in Cos-7 cells in the presence or absence of R1881 were
immunoprecipitated (first IP) with an anti-Flag antibody and immunoblotted using an antibody against AR (left two lanes). A secondary
immunoprecipitation was performed on the supernatant after first IP using antibody specifically against acetylated lysine and immunoblotted
with an anti-AR antibody (right two lanes). (F) Flag-HSP90 co-transfected with AR-WT, or -618R, or -618Q into Cos-7 cells, respectively.
Post-transfection, cells were exposed to ethanol or R1881 for one hour. HSP90-bound AR was measured by immunoprecipitation with an
anti-Flag antibody and immunoblotted with an anti-AR antibody.
www.impactjournals.com/oncotarget
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AR-HSP90 dissociation, AR target gene expression,
and PCa cell growth. Targeting ARD1-mediated AR
acetylation and AR-HSP90 dissociation without disrupting
the critical functions of HSP90 may prove to be a potent
alternative to HSP90 inhibition while simultaneously
avoiding the deleterious effects of androgen deprivation
therapy.

AB3282). HRP-conjugated secondary antibodies used
were from Sigma. Immunoprecipitation was performed
using lysis/wash buffer [50 mM Tris-HCl (pH = 7.4),
150 mM NaCl, 1 mM EDTA, 1% Triton-X, 1× protease
inhibitor cocktail]. Protein G agarose beads (Thermo
20399) were used to immunoprecipitate target proteins.

Plasmids and transient or stable transfection

MATERIALS AND METHODS

The FLAG-ARD1 construct was generated as
previously described [22]. The PSA-luciferase (PSA-luc)
reporter was kindly provided by Dr. Haojie Huang (Mayo
Clinic). The pLenti-AR construct was generously provided
by Dr. Yan Dong (Tulane University), and subsequent
mutant AR and ARD1-dead constructs were generated
using Quikchange XL site-directed mutagenesis kit (Life
Technologies). Transient transfections of plasmids were
performed using Transit-X2 transfection reagent (Mirus)
according to the manufacturer’s recommendations. Stable
DU 145 cells expressing WT or mutant AR were generated
using Virapower lentiviral packaging kit (Invitrogen)
according to the manufacturer’s recommendations.

Cell lines
HEK293T, DU 145, LNCaP, and Cos-7 cells were
purchased from the American Type Culture Collection
(ATCC). Cells were maintained in appropriate media per
the ATCC guidelines. Where applicable, cells were treated
with deacetylation inhibition cocktail (sc-362323) diluted
in DMSO.

Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation were
performed as previously described [28]. The primary
antibodies utilized in this study include androgen receptor
(AR) (sc-7305 and sc-815), ARD1 (sc-33820), acetylated
lysine (sc-32268), mouse IgG (sc-2025), and His (sc-804)
(Santa Cruz Biotechnology); β-actin (A5441) and FLAG
(F3165) (Sigma); RNA polymerase II (AbCam 5408);
HSP90 (Thermo Pierce PA3-013); GST (Chemicon

In vitro and in vivo acetylation assay
The in vitro acetylation assay on AR was
performed using His-ARD1 as described previously with
modification [22]. Briefly, GST-tagged AR fragments were
grown overnight in BL21 E. coli cells, induced by .1 mM

Figure 6: Schematic for the mechanism of ARD1-mediated AR acetylation in prostate tumorigenesis: (A) with limited
androgen, ARD1, AR, and HSP90 form a complex in prostate cells. (B) Following exposure to androgen, ARD1 acetylates AR

resulting in dissociation of acetylated AR from HSP90 and ARD1. (C) Acetylated AR is translocated into nuclei and binds to ARE and RNA
Pol II for AR target gene expression and prostate tumorigenesis. (D) Inhibition of ARD1 or ARD1-mediated AR acetylation may prevent
AR nuclear entry and androgen-dependent prostate tumorigenesis.
www.impactjournals.com/oncotarget

71425

Oncotarget

IPTG for 2 hours. GST-AR fragments were purified using
glutathione beads (GE Healthcare 17-0756-01), eluted
with reduced glutathione, and dialyzed for 24 hours
using Slide-A-Lyzer .5–3 ml dialysis cassettes (Thermo
66380). His-ARD1 was purified using a His SpinTrap
Kit (GE Healthcare 28-4013-53) per the manufacturer’s
recommendations. The in vitro acetylation assay was
performed and proteins were separated by SDS-PAGE.
Corresponding amounts of each fragment were separated
by SDS-PAGE and stained with Coomassie blue stain.
Cell proliferation and anchorage-independent growth
assays. Cell proliferation MTT assays were performed
with DU 145 cell pools stably expressing WT or mutant
AR using CellTiter 96 Non-Radioactive Cell Proliferation
Assay (Promega) kit according to the manufacturer’s
recommendations. Colonogenic growth of stable cells
was analyzed by evaluation of growth in soft agar 17 days
post-plating, as described previously [29].

DU 145 cells were transiently transfected with vectors
either expressing WT or K618-mutantAR. PCR was
performed with previously reported primers [22], and the
relative enrichment was demonstrated using agarose gel
electrophoresis.

Xenograft tumor growth

Statistical analysis

Stable DU 145 cell pools expressing WT or mutant
AR (n = 3 mice per group. 2.5 × 106 cells/injection) were
injected into the hind flanks of nude mice (Charles River)
as previously described [22]. Growth was monitored by
caliper measurement over the course of 10 weeks. All
procedures follow an animal use protocol approved by the
Institutional Animal Care and Use Committee of Louisiana
State University Health Sciences Center in New Orleans.

Data are expressed as mean ± SD from at least
3 experiments. Statistical analyses were performed by
Student’s t test. P < 0.05 was considered statistically
significant.

Nuclear entry assay
Cos-7 cells were plated on chamber slides in phenol
red-free RPMI 1640 media with 10% charcoal-depleted
FBS. Cells were transfected after 24 hours with either ARWT, AR-618R, or AR-618Q. Cells were treated with 1 nM
R1881 for one hour 24 hours post-transfection. Cells were
embedded on slides with paraformaldehyde, permealized
with .25% triton-x, blocked with 5% goat serum, and
probed with anti-AR antibody (sc-7305) overnight. Antimouse secondary antibody (Alexa Fluor 448) was applied,
as well as Hoechst stain (Thermo 33342) specific for DNA.
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Luciferase reporter assays
DU 145 cells were transfected with a combination
of plasmids, including either PSA-Luc, as well as a vector
containing either WT or 618K-mutant AR, and an internal
control (pRL-TK), and serum-starved for 24 hours. Cells
were then subjected to 24 hours of R1881 exposure.
Analysis was performed using the Dual-Luciferase
Reporter Assay system (Promega) per the manufacturer’s
instructions.

Quantitative RT-PCR
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Total RNAs were prepared using the RNeasy kit
(Qiagen) and cDNA was synthesized using Superscript III
First-Strand synthesis system (Invitrogen). Quantitative
RT-PCR (qRT-PCR) was performed using SYBR Green
detection method on a CFX96 Real-Time PCR detection
system (BIO-Rad). All of the primers used for this study
have been reported [22].
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